Clinical comparison of bronchial artery infusion of cisplatin and mitomycin C in primary non-small cell lung cancer.

DOI Web Site
  • Hisada Tetsuya
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Kudoh Shoji
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Teratani Keiko
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Uetake Kenji
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Hirayama Masakiyo
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Hsu Lung-Hung
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Kimura Hitoshi
    Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital
  • Suzuki Kenzo
    Department of Radiology, Tokyo Metropolitan Komagome Hospital
  • Ikeda Takaaki
    Department of Thoracic Surgery Tokyo Metropolitan Komagome Hospital
  • Sakai Tadaaki
    Department of Thoracic Surgery Tokyo Metropolitan Komagome Hospital
  • Sakai Shoji
    Department of Thoracic Surgery Tokyo Metropolitan Komagome Hospital
  • Fukayama Masashi
    Department of Pathology Tokyo Metropolitan Komagome Hospital
  • Koike Morio
    Department of Pathology Tokyo Metropolitan Komagome Hospital

Bibliographic Information

Other Title
  • 原発性肺がんに対するｃｉｓｐｌａｔｉｎ気管支動脈内注入の臨床的検討　　マイトマイシンＣとの比較
  • small Cell Lung Cancer
  • マイトマイシンCとの比較

Search this article

Description

Bronchial artery infusion (BAI) of 25mg of cisplatin was performed in 25 patients with primary non-small cell lung cancer. No severe side effects were observed after the procedure. No patients showed 50% or greater tumor reduction and only 3 patients showed 20% or greater tumor reduction at 2 weeks after BAI. The tumor reduction rate of this group was smaller than that of 47 cases treated with a combination of BAI of mitomycin C and systemic administration of vincristin (p<0.01). These results suggest that the infusion time, dosage and metabolism of cisplatin must be studied further before it can be used as a cytotoxic drug for BAI.

Journal

  • Haigan

    Haigan 26 (1), 65-71, 1986

    The Japan Lung Cancer Society

Keywords

Details 詳細情報について

Report a problem

Back to top